Comunicados de prensa de Moderna

NeOnc’s encouraging brain-cancer survival findings join 20206 developments from $RVMD, $MRNA, $MRK, $JNJ, $GMAB and $ABBV.

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index ® (NDX ® ) replacing Warner Bros. Di…

(PR-inside.com) Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 /…

(PR-inside.com) Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an…

(PR-inside.com) Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna will also purcha…

(PR-inside.com) mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA…

(PR-inside.com) Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our…

(PR-inside.com) CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumo…

(PR-inside.com) Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NA…

(PR-inside.com) Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration betw…

(PR-inside.com) At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in th…

(PR-inside.com) Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA…